Eli Lilly And Company Patent Portfolio Statistics

Eli Lilly And Company

Eli Lilly And Company`s Profile

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Eli Lilly And Company look like?

Total Applications:	2219
Granted Patents:	1367
Grant Index	77.94 %
Abandoned/Rejected Applications:	387 (22.06%)
In-Process Applications:	462
Average Grant Time:	2.51 Years
Average Office Actions:	1.28

Which Technology Area Eli Lilly And Company is filing most patents in? (Last 10 years)

Art Unit	Definition	Total Applications
1625	Organic Chemistry	223
1624	Organic Chemistry	183
1626	Organic Chemistry	174
1614	–	117
1654	Fermentation, Microbiology, Isolated and Recombinant Proteins/Enzymes	84

How many patents are Eli Lilly And Company filing every year?

Year	Total Applications
2022	0*
2021	68*
2020	65
2019	55
2018	39

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Eli Lilly And Company in USPTO?

Publication number: US20220025009A1

Abstract:
PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.

Publication date: 2022-01-27
Applicant: Eli Lilly And Company
Inventors: Anthony Briere Daniel

Publication number: US20220017496A1

Abstract:
The present invention provides a compound of Formula I.or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Publication date: 2022-01-20
Applicant: Eli Lilly And Company
Inventors: Barrett Durham Timothy

Publication number: –

Abstract:
None

Publication date: –
Applicant: Eli Lilly And Company
Inventors: Dinesh Mishra Shyamdeo

How are Eli Lilly And Company’s applications performing in USPTO?

Application Number	Title	Status	Art Unit	Examiner
17494394	Protein Tyrosine-Tyrosine Analogs And Methods Of Using The Same	–	OPAP	Central, Docket
17478080	Disubstituted Pyrazole Compounds	–	OPAP	Central, Docket
17438692	Preserved Formulations	–	–	–
17473173	Methods Of Selecting And Detecting Binding Peptides	Docketed New Case – Ready for Examination	OPAP	Central, Docket
17465066	Selective Estrogen Receptor Degraders	Docketed New Case – Ready for Examination	OPAP	Central, Docket